

# CURRICULUM VITAE

Marie-Térèse, E., Little, BSc., MSc., PhD

---

## PERSONAL DATA

Place of Birth: Calgary, Alberta, Canada  
Citizenship: Canada

## EDUCATION

09/81 to 04/86 BSc., University of Victoria, Victoria, BC, Canada  
05/84 to 07/84 French Immersion, Université Sainte-Anne, Pointe-de-l'Église,  
Nouvelle-Écosse, Nova Scotia, Canada  
09/87 to 04/90 MSc., University of British Columbia (UBC), Vancouver, BC, Canada  
09/90 to 07/96 PhD., Terry Fox Laboratory for Haematology/Oncology,  
University of British Columbia (UBC), Vancouver, BC, Canada

## POSTGRADUATE TRAINING

09/96 to 02/97 Post-doctoral Fellowship, Terry Fox Laboratory for Haematology/  
Oncology, BC Cancer Agency, Vancouver, BC, Canada  
03/97 to 08/98 Post-doctoral Fellowship, Dana-Farber Cancer Institute, Harvard  
University, Boston, MA  
08/98 to 10/99 Research Associate Fellowship, Beth Israel Deaconess Medical Center,  
Harvard University, Boston, MA

## FACULTY POSITIONS

10/99 to 05/05 Staff Scientist, Fred Hutchinson Cancer Research Center, Seattle, WA  
04/07 to 12/06 Affiliate, Fred Hutchinson Cancer Research Center, Seattle, WA

## HONORS

1992 University Graduate Fellowship, UBC, British Columbia, Canada  
1999 Leukemia Research Foundation, USA (declined)  
1999 Lady Tata Memorial Trust, UK  
2000 Lady Tata Memorial Trust, UK  
2001 Muscular Dystrophy Association, Special Research Grant, USA

## PROFESSIONAL ORGANIZATIONS

1999 to 2004 American Society of Hematology, Member

## EDITORIAL RESPONSIBILITIES

1999 to 2004 Blood Journal, Reviewer  
2018 to present Current Oncology, Reviewer

## SPECIAL NATIONAL RESPONSIBILITIES

2004 Skeletal Muscle and Exercise Physiology Study Section SMEP  
(Skeletal Muscle and Exercise Physiology) and Orth SBIR, Center for  
Scientific Review, National Institutes of Health {2004/10 ZRG1  
MOSS-H(14) (S) (Orth SBIR Standing SEP) 07/25/2004 -07/25/2004  
and 2004/10 SMEP 06/24/2004 - 06/25/2004 Study Sections

## CURRICULUM VITAE

Marie-Térèse, E., Little, BSc., MSc., PhD

---

### SPECIAL LOCAL RESPONSIBILITIES

2008 to present	Patient Advocate/ Health Care Navigator, Victoria, BC, Canada
2008 to present	President and Principal Consultant, 4 <sup>th</sup> Dimension Biomedical & Research Communications (4Dbrc.com)
2009 to 2016	Member, Clinical Research Ethics Board (CREB / IRB) Vancouver Island Health Authority, Victoria, BC, Canada
2012 to 2015	Chair, Clinical Research Ethics Board (CREB / or IRB) Vancouver Island Health Authority, Victoria, BC, Canada
2015 to present	Canadian Cancer Clinical Trials Group; Queen's University, Kingston, Ontario, Canada (Remote)- Lay Representative & Patient Advocacy/ Communications, Gastrointestinal Disease Site Executive Committee

### RESEARCH FUNDING, PAST AND CURRENT

#### PAST:

	Fred Hutchinson Cancer Research Center, Seattle, WA
1999 – 2004	P01 CA78902, “Mixed Hematopoietic Chimerism After Stem Cell Allografts”. NIH/NCI. Storb, R, PI. <b>Little, MT</b> (Investigator and Core B Leader). Direct costs: \$2,019,270 USD
2000 - 2001	Industry, “Use of CTLA4Ig to Establish Mixed Chimerism in DLA-Identical Littermate Bone Marrow Transplantation”. Repligen. <b>Little, MT</b> , PI. Direct costs: \$78,000 USD
2001 - 2006	P01 CA 18029, “Adult Leukemia Research Center”. NIH/NCI. Appelbaum, F. PI. <b>Little, MT</b> (Investigator), Direct costs: \$6,907,510 USD
2001 – 2009	MDA TE 3089, “Allogeneic Stem Cell Transplantation in the Canine DMD Model”. <b>Little, MT</b> , PI. Direct costs: \$200,000 USD
2002 – 2004	IND TE 3433, “AMD-3100 for Hematopoietic Stem Cell Mobilization in the Canine Autologous Transplantation Model”. <b>Little, MT</b> , PI. Direct costs: \$422,336 USD
2003 -2008	U54 HD47175, “Muscular Dystrophy Cooperative Research Center”. Chamberlain, J, PI. <b>Little, MT</b> (Project Leader, Sub-Project 2) Direct Costs: \$1,000,000 USD

### BIBLIOGRAPHY

#### PEER REVIEWED JOURNAL ARTICLES

1. **Little MTE**, Hahn P. Ontogeny of acyl-CoA: cholesterol acyltransferase in rat liver, intestine, and adipose tissue. *Am. J. Physiol.* 262 (Gastrointestinal Liver Physiol. 25) G599-G602, 1992.
2. Craig W, Poppema S, **Little M-T**, Dragowska W, Lansdorp P. CD45 isoform expression on human haematopoietic cells at different stages of development. *Br J Haematol* 88:24-30, 1994.
3. Lansdorp PM, Dragowska V, Thomas TE, **Little M-T**, Mayani H. Age-related decline in proliferative potential of purified stem cell candidates. *Blood Cells* 20:376-381, 1994.
4. Mayani H, **Little M-T**, Dragowska W, Thornbury G, Lansdorp PM. Differential effects of the hematopoietic inhibitors MIP-1 $\alpha$ , TGF $\beta$  and TNF $\alpha$  on multiple cytokine-induced proliferation of CD34<sup>+</sup> cells from cord blood and fetal liver. *Exp Haem* 23:422-427, 1995.

5. Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, **Little M-T**, Dirks RW, Raap AK, Tanke HJ. Heterogeneity in telomere length of human chromosomes. *Hum Mol Genet* 5:685-691, 1996.
6. **Little M-T**, Langlois S, Wilson D, Lansdorp PM. Frequency of fetal cells in sorted subpopulations of nucleated erythroid and CD34+ hematopoietic progenitor cells from maternal peripheral blood. *Blood* 89:2347-2358, 1997.
7. Uemura N, Salgia R, **Little M-T**, Griffin JD. Involvement of the adapter protein CRKL in integrin-mediated adhesion. *Oncogene* 18; 3343-3353, 1999.
8. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Liu L-Q, **Little M-T**, Zhang DE. Inducible AML1-ETO Expression in Transgenic Mice. *Blood* 96: 2108-2115, 2000.
9. Schwer H, Liu LQ, Zhou L, **Little M-T**, Hetherington C, Zhang DE. Cloning and Characterization of Human Ubiquitin-Specific Protease, a homologue of murine UBP43 (USP18), *Genomics* 65-44-52, 2000.
10. Storb R, Sale G, Barnett T, Yu C, Zellmer E, **Little M-T**. Transient mixed hematopoietic chimerism in dogs given thymic irradiation before and pharmacologic immunosuppression after marrow transplantation. *Blood* 97: 2915-2916, 2001.
11. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, **Little M-T**, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem H-P, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic cell transplantation: replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. *Ann NY Acad Sci* 938: 328-339, 2001.
12. Georges GE, Storb R, Bruno B, Brodie SJ, Thompson JD, Taranova AG, Zaucha JM, **Little M-T**, Zellmer E, Moore PF, Gooley T, Sale G, Kiem H-P, Sandmaier BM, Lyons RM, Nash RA. Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. *Blood* 98: 3447-3455, 2001.
13. Zaucha JM, Zellmer E, Georges G, **Little M-T**, Storb R, Storer B, Torok-Storb B. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. *Biol Blood Marrow Transplant* 7: 613-619, 2001.
14. Zaucha JM, Yu C, Zellmer E, Takatu A, Junghanss C, **Little M-T**, Storb R. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. *Biol Blood Marrow Transplant* 7: 513-516, 2001.
15. Zaucha JM, Yu C, Mathioudakis G, Seidel K, Georges G, Sale G, **Little M-T**, Torok-Storb B, Storb R. Hematopoietic responses to stress conditions in young dogs compared with elderly dogs. *Blood* 98: 322-327, 2001.
16. Georges GE, Maris M, Sandmaier BM, Maloney DG, Feinstein L, Niederwieser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, **Little M-T**, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. *Int J Hematol* 76 (Suppl. I): 184-189, 2002.

17. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, **Little M-T**, Corey L, Storb R. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. *Blood* 99: 1978-1985, 2002.
18. Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, Zellmer E, **Little M-T**, Torok-Storb B, Storb R. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. *Transplantation* 73: 1487-1493, 2002.
19. Lee R, Storb R, **Little M-T**, Joslyn A, Spector M, Kuhr CS. Percutaneous central dual-lumen catheter for apheresis in the canine. *J Invest Surg* 15: 337-341, 2002.
20. Ritchie KJ, Malakhov MP, Hetherington CJ, Zhou L, **Little MT**, Malakhova OA, Sipe JC, Orkin SH, Zhang DE. Dysregulation of protein modification by ISG15 results in brain cell injury. *Genes Dev* 16: 2207-2212, 2002.
21. Xun C-Q, **Little M-T**, Zellmer E, Yu C, Zaucha JM, Sale GE, Storer B, Storb R. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? *Transplantation* 73: 310-313, 2002.
22. Yunusov MY, Kuhr C, Georges GE, Sale GE, Spector M, Lesnikova M, Lee R, **Little M-T**, Gass MJ, Weber K, Joslyn A, Storb R, Nash RA. Survival of small bowel transplants in canine mixed hematopoietic chimeras: preliminary results. *Transplant Proc* 34: 3366-3367, 2002.
23. Zaucha JM, Mielcarek M, Takatu A, **Little M-T**, Gooley T, Baker J, Maloney DG, Sandmaier BM, Maris M, Chauncey T, Storb R, Torok-Storb B. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. *Br J Haematol* 119: 740-750, 2002.
24. Georges GE, Lesnikova M, Storb R, Yunusov M, **Little M-T**, Nash RA. Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates. *Blood and Marrow Transplantation Reviews* 13: 9-10, 2003.
25. Georges GE, Lesnikova M, Storb R, Yunusov M, **Little M-T**, Nash RA. Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates. *Biol Blood Marrow Transplant* 9: 234-242, 2003.
26. Hogan WJ, **Little M-T**, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S, Lee R, Kuhr C, Storb R. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. *Biol Blood Marrow Transplant* 9: 489-495, 2003.
27. Junghanss C, Takatu A, **Little M-T**, Zaucha JM, Zellmer E, Yunusov M, Sale G, Georges GE, Storb R. Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras. *Transplantation* 75: 268-274, 2003.
28. Lee RS, Kuhr CS, Sale GE, Zellmer E, Hogan WJ, Storb R, **Little M-T**. FTY720 does not abrogate acute graft-versus-host disease in the DLA-nonidentical unrelated canine model. *Transplantation* 76: 1155-1158, 2003.

29. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, **Little M-T**, Blume KG, McSweeney PA, Storb RF. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. *Blood* 101: 1620-1629, 2003.
30. Storb R, Sandmaier BM, Forman S, Maris M, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Stuart MJ, Hegenbart U, Sahebi F, Bruno B, Agura E, **Little M-T**, Niederwieser D. What role for nonmyeloablative conditioning in allogeneic hematopoietic cell transplantation? *Acta Haematologica Polonica* 34 (Suppl. 1): 17-20, 2003.
31. Takatu A, Nash RA, Zaucha JM, **Little M-T**, Georges GE, Sale GE, Zellmer E, Kuhr CS, Lothrop CD, Jr., Storb R. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia. *Biol Blood Marrow Transplant* 9: 674-682, 2003.
32. Yunusov MY, Georges GE, Storb R, Moore P, Hagglund H, Affolter V, Lesnikova M, Gass MJ, **Little M-T**, Loken M, McKenna H, Storer B, Nash RA. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. *Transplantation* 75: 933-940, 2003.
33. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, Maloney DG, Heimfeld S, Oparin D, Zellmer E, Radich JP, Grumet FC, Blume KG, Chauncey TR, **Little M-T**. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *Blood* 104: 2254-2262, 2004.
34. Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, Hauschka SD, Lee RS, Sale GE, Zellmer E, Gisburne S, Bogan J, Kornegay JN, Cooper BJ, Gooley TA, **Little M-T**. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. *Blood* 104: 4311-4318, 2004.
35. Lee J-H, Joo Y-D, Yim D, Lee R, Ostrander EA, Loretz C, **Little M-T**, Storb R, Kuhr CS. Molecular cloning and characterization of canine ICOS. *Genomics* 84: 730-736, 2004.
36. Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR, Sorrow M, **Little M-T**, Maloney DG, Storb R, Heimfeld S. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. *Leukemia* 19: 822-828, 2005.
37. Burroughs L, Mielcarek M, **Little M-T**, Bridger G, MacFarland R, Fricker S, LaBrecque J, Sandmaier BM, Storb R. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral blood mononuclear cells in a canine transplantation model. *Blood* 106: 4002-4008, 2005.
38. Diaconescu R, **Little M-T**, Leisenring W, Yunusov M, Hogan WJ, Sorrow ML, Baron F, Storb R. What role is there for antithymocyte globulin in allogeneic nonmyeloablative

- canine hematopoietic cell transplantation? *Biol Blood Marrow Transplant* 11: 335-344, 2005.
39. Panse JP, Heimfeld S, Guthrie KA, Maris MB, Maloney DG, Baril BB, **Little M-T**, Chauncey TR, Storer BE, Storb R, Sandmaier BM. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimerism and later clinical outcomes after nonmyeloablative conditioning. *Br J Haematol* 128: 659-667, 2005.
  40. Wang, Z, Blankinship, M, Gregorevic P, **Little M-T**, Storb, RJ, Allen, JM, Tapscott, SJ, Chamberlain JS & Kuhr, CS. Immunity to AAV-Mediated Gene Therapy in a Random-Bred Canine Model of Duchenne Muscular Dystrophy *Molecular therapy* 11: 307-319, 2005.
  41. Baron F, **Little M-T**, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. *Blood Rev* 19: 153-164, 2005.
  42. Kuhr CS, Lupu M, **Little M-T**, Zellmer E, Sale GE, Storb R. RDP58 does not prevent graft-versus-host disease after dog leukocyte antigen-nonidentical canine hematopoietic cell transplantation. *Transplantation* 81: 1460-1462, 2006.
  43. Lupu M, Sullivan EW, Westfall TE, Little M-T, Weigler BJ, Moore PF, Stroup PA, Zellmer E, Kuhr C, Storb R. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. *J Am Vet Med Assoc* 228: 728-732, 2006.
  44. Baron F, **Little MT**, Storb R. Non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation. In: Sekeres MA, Kalaycio ME, Bolwell BJ, editors. *Clinical Malignant Hematology*. New York, NY: McGraw-Hill Companies; 2007. p. 1025-38.
  45. Venkataraman GM, Kennedy LJ, **Little MT**, Graves SS, Harkey MA, Torok-Storb BJ, Storb R. Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. *HLA*. 2017;90(3):165-70. Epub 2017 Jul 5. doi: 10.1111/tan.13077. PubMed PMID: 28677267; PMCID: PMC5551428
  46. Waldorf Adams K, Olson E, Nelson B, **Little MTE**, Rajagopal L. The Aftermath of Zika: Need for Long-Term Monitoring of Exposed Children. *TIM*, 2018. DOI: <https://doi.org/10.1016/j.tim.2018.05.011>

#### BOOK CHAPTERS

1. Lansdorp PM, Rebel VI, Dragowska W, Little MTE, Thomas TE, Humphries RK, Eaves CJ, Mayani H. Proliferative and differentiation potential of neonatal and fetal hematopoietic stem cells, In: Gluckman, E., Coulombel, L (eds): *Ontogeny of hematopoiesis: Aplastic anemia*. Montrouge: John Libbey Eurotext Ltd, p. 49-52, 1995.
2. Lansdorp PM, Smith C, Thornbury G, Little M-T, Dragowska W. Reactivity of Workshop mAb with CD34+ bone marrow cells. *Leucocyte Typing V: White cell differentiation Antigens*. eds. Schlossman, S.F. et al., Oxford University Press, Oxford 1030-1032, 1995.

## CURRICULUM VITAE

Marie-Térèse, E., Little, BSc., MSc., PhD

---

3. Storb R, Sandmaier BM, Forman S, Maris M, Feinstein L, Chauncey T, Maloney DG, McSweeney PA, Blume KG, Shizuru J, Hegenbart U, **Little M-T**, Niederwieser D. Haematopoietic cell transplantation from siblings in older patients with haematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. In: Schultze W (ed): Proceedings of the 5th International Stem Cell Workshop: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells (2001). Berlin, Germany: Blackwell Publishing Ltd, p. 3-6, 2002.
4. Baron F, Little M-T, Storb R. Non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation. In: Sekeres MA, Kalaycio ME, Bolwell BJ (eds): Clinical Malignant Hematology. New York, NY: McGraw-Hill Companies, p. 1025-1038, 2007.

### OTHER PUBLICATIONS

1. Lansdorp PM, Dragowska V, **Little M-T**, Craig W, Mayani H. Studies of haematopoietic differentiation pathways using highly purified progenitor cells in serum-free culture. XVI Congress of the International Society for Analytical Cytology. Colorado Springs, CO. U.S.A. March 1993.
2. Thomas TE, Phillips GL, Humphries RK, Horsman DE, Gascoyne RD, **Little M-T**, Lansdorp PM. Positive selection of CD34+ cells from Human bone marrow for indirect purging of non-Hodgkin's lymphoma cells. *Cancer Res Ther Control* 4:2 119-128, 1994.
3. Lansdorp PM, Smith C, Thornbury G, **Little M-T**, Dragowska W. Reactivity of Workshop mAb with CD34+ bone marrow cells. *Leucocyte Typing V: White cell differentiation Antigens*. eds. Schlossman, S.F. et al., Oxford University Press, Oxford 1030-1032, 1995.
4. Spangrude GJ, Torok-Storb B, **Little M-T**. Chimerism of the transplanted heart (Letter to Editor). *N Engl J Med* 346: 1410, 2002.
5. Fagerlie, S and **Little, MT**. Advances in the management of hematologic malignancies: Highlights from the 2012 American Society of Clinical Oncology Annual Meeting. Educational Concepts Group newsletter publication. Jabbour E, Williams ME, eds. Atlanta, Georgia, p.1-33, 2012.
6. Fagerlie, S and Little, MT. Advances in the management of hematologic malignancies: Highlights from the 2013 American Society of Clinical Oncology Annual Meeting. Educational Concepts Group newsletter publication. Appelbaum FR, Flowers CR, Wolf JL, eds. Atlanta, Georgia, p.1-24, 2013.

### MANUSCRIPTS SUBMITTED

1. Walker, C, Waldorf Adams K, Olson E, Nelson B, **Little MTE**, Rajagopal L. Zika Virus and the Non-Microcephalic Fetus: Why We Should Still Worry *AJOG* May, 2018

### ABSTRACTS (selected)

1. **Little MTE** and Hahn P. Acyl-CoA: cholesterol acyltransferase in rat liver, intestine, adipose tissue and aorta. *Proc. Can. Fed. Biol. Sci. Abstract* 451, (1989). (Abstract)
2. **Little MTE** and Hahn P. Acyl-CoA: cholesterol acyltransferase in rat liver, intestine, adipose tissue and aorta during development in the rat. *Canada W Soc Reproductive Biol Abstract* 4, (1990). (Abstract)

3. Lansdorp PM, Dragowska V, **Little M-T**, Craig W, Mayani H: Studies of haematopoietic differentiation pathways using highly purified progenitor cells in serum-free culture. *Cytometry (Suppl 6)*: 70, 1993. (Abstract)
4. Lansdorp PM, Smith C, Thornbury G, **Little M-T** and Dragowska W: Reactivity of workshop mAb with CD34+ bone marrow cells. *Tissue Antigens* 42:454, 1993. (Abstract)
5. **Little M-T**, Smith C, Lansdorp PM. The isolation and characterisation of monoclonal antibodies for enrichment of fetal cells in maternal blood. *ASHG*, 1994. (Abstract)
6. Lansdorp PM, Dragowska V, **Little M-T**, Chen J, Thomas TE, Chiu C-P, Harley CB, Kim NW, Vverwoerd NP, van de Rijke FM, Dirks RW, Raap AK, Tanke HJ. Telomere dynamics in hematopoietic cells. *Blood* 86 (Suppl 1): 590a, 1995. (Abstract)
7. **Little M-T**, Langlois S, Wilson D, Lansdorp PM. Frequency of fetal nucleated erythroid cells and CD34+ progenitor cells in sorted subpopulations of first trimester maternal blood isolated by flow cytometry and FISH. *ASHG*, October 30, 1996. (Abstract)
8. Georges, G.E., Lesnikova, M., Storb, R., Kuo, M., **Little, M.T.**, Heimfeld, S., Nash, R.A. Minor-histocompatibility antigen (miHA)-specific cytotoxic t-lymphocytes (CTL) generated with dendritic cells (DC) between dog leukocyte antigen (DLA)-identical littermates. *Blood* 96 (Part 1): 770a, #3332, 2000. (Abstract)
9. Junghanss, C., Yunusov, M., Zaucha, J.M., Takatu, A., **Little, M.T.**, Zellmer, E., Georges, G., Nash, R., Torok-Storb, B., Storb, R. Hematopoietic mixed chimerism in a canine model as platform to induce allogeneic graft-vs-kidney effects. *Blood* 96 (Part 1): 770a-771a, #3333, 2000. (Abstract)
10. Kuhr CS, Allen MD, Junghanss C, Yunusov M, Torok-Storb B, **Little M-T**, Storb R. Tolerance to vascularized kidney grafts induced through stable mixed hematopoietic chimerism. *Blood* 96 (Part 1): 764a, #3305, 2000.(Abstract)
11. Maris MB, Sandmaier BM, Niederwieser D, Gooley T, Maloney DG, McSweeney PA, Shizuru J, Sahebi F, Little MT, Forman S, Blume K, Storb R. Comparisons of donor chimerism, graft rejection, and GVHD after hematopoietic stem cell transplants (HSCT) from HLA matched siblings and unrelated donors using conditioning with 2 Gy TBI with and without fludarabine (FLU). *Blood* 96 (Part 1): 520a, #2239, 2000.(Abstract)
12. Zaucha JM, Yu C, Zellmer E, Takatu A, Junghanss C, **Little MT**, Storb R. Extending the duration of postgrafting cyclosporine (CSP) but not substituting G-CSF mobilized peripheral blood mononuclear cells (G-PBMC) for marrow enhances allogeneic engraftment in a nonmyeloablative canine transplant model. *Blood* 96 (Part 1): 763a, #3301, 2000. (Abstract)
13. **Little, M.-T.**, Zellmer, E., Friedetzky, A., Georges, G., Storb, R. Immunosuppression with rapamycin and cyclosporine after allogeneic nonmyeloablative marrow transplant in a preclinical large animal model. *Blood* 98 (Part 1): 169a, #714, 2001. (Abstract)
14. **Little, M.-T.**, Baker, J., Sandmaier, B., Maris, M., Maloney, D., Gooley, T., Zellmer, E., Heimfeld, S., Georges, G., Wagner, J., Shizuru, J., Blume, K., Chauncey, T., Storb, R. Analysis of mixed chimerism in peripheral blood hematopoietic subpopulations from 101 patients after nonmyeloablative hematopoietic stem cell transplant. *Blood* 98 (Part 1): 477a, #1992, 2001. (Abstract)



15. Maris M, Niederwieser D, Sandmaier B, Maloney D, Shizuru J, Petersdorf E, Blume K, Chauncey T, Pulsipher M, McSweeney P, Storer B, Anasetti C, Woolfrey A, Slattery J, Agura E, **Little M-T**, Hegenbarth U, Storb R. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. *Blood* 98 (Part 1): 858a, #3563, 2001.(Abstract)
16. Takatu, A., Zaucha, J.M., **Little, M.-T.**, Georges, G.E., Zellmer, E., Nash, R., Lothrop, C.D., Storb, R. Nonmyeloablative bone marrow transplant plus sensitized donor lymphocyte infusion as an option for cure of hereditary hemolytic anemia (pyruvate kinase deficiency). *Blood* 98 (Part 1): 171a, #720, 2001. (Abstract)
17. Lesnikova, M., Poor, R., Lesnikov, V., Deeg, H.J., Nash, R.A., **Little, M.-T.**, Georges, G.E. Transferrin (Tf) modulates allogeneic interactions. *Blood* 98: 326b, #5064, 2001. (Abstract)
18. Junghanss, C., **Little, M.-T.**, Avasare, S., Lesnikova, M., Zaucha, J.M., Georges, G.E., Nash, R., Storb, R. Use of dendritic cell vaccines in mixed hematopoietic canine littermates. *Blood* 98 (Part 2): 317b, #5027, 2001. (Abstract)
19. Friedetzky A, Hogan WJ, Renneberg H, Zellmer E, **Little M-T**, Storb R. Realtime quantitative PCR proves to be superior to VNTR in the evaluation of hematopoietic microchimerism in recipients of a sex mismatched HSCT in a canine model. *Blood* 100 (Part 2): 405b, #5185, 2002.(Abstract)
20. Yunusov, M.Y., Kuhr, C., Storb, R., Georges, G.E., Lesnikova, M., **Little, M.-T.**, Sandmaier, B.M., Nash, R.A. Marrow donor skin grafts in a canine DLA-identical model of stable mixed donor/host hematopoietic chimerism. *Blood* 100 (Part 1): 404a, #1571, 2002. (Abstract)
21. Hogan WJ, **Little M-T**, Zellmer E, Kuhr C, Diaconescu R, Storb R. Marrow engraftment after nonmyeloablative conditioning followed by postgrafting immunosuppression with sirolimus and cyclosporine in the canine model. *Blood* 100 (Part 1): 405A, #1574, 2002.(Abstract)
22. Kuhr CS, Yunusov M, **Little M-T**, Zellmer E, Marsh CL, Torok-Storb B, Storb RF. Effects of tissue restricted minor antigens in kidney and skin on immune tolerance in a large animal model of mixed hematopoietic chimerism. *Blood* 100 (Part 1): 404a, #1570, 2002.(Abstract)
23. **Little M-T**, Baker JE, Sandmaier BM, Maris MB, Maloney D, Gooley T, Oparin D, Zellmer E, Mielcarek M, Wagner J, Shizuru J, Blume K, Chauncey T, Storb R. Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. *Blood* 100 (Part 1): 39a, #136, 2002.(Abstract)
24. Maris MB, Niederwieser D, Sandmaier B, Maloney D, Shizuru J, Petersdorf E, Blume K, Pulsipher M, McSweeney P, Chauncey T, Storer B, Slattery J, Woolfrey A, Agura E, Hegenbarth U, Feinstein L, **Little M**, Anasetti C, Storb R. Engraftment of nonmyeloablative hematopoietic stem cell transplants (HSCT) using marrow and PBSC from 10/10 HLA antigen matched unrelated donors (URDs) for patients ineligible for conventional HSCT. *Biol Blood Marrow Transplant* 8: 63, #8, 2002.(Abstract)

25. Maris MB, Niederwieser D, Sandmaier BM, Maloney DG, Shizuru J, Petersdorf E, Storer B, Pulsipher M, McSweeney P, Slattery J, Woolfrey A, Agura E, Chauncey T, **Little M-T**, Hegenbarth U, Anasetti C, Blume K, Storb R. Nonmyeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies. *Blood* 100 (Part 1): 76a, #275, 2002.(Abstract)
26. Sandmaier BM, Maris M, Maloney DG, Gooley TA, Stuart MJ, Hegenbart U, Sahebi F, Chauncey T, Agura E, Bruno B, McSweeney PA, Maziarz R, Pulsipher M, Epner E, **Little M-T**, Forman SJ, Niederwieser DW, Blume KG, Storb R. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. *Blood* 102 (Part 1): 78a-79a, #264, 2003.(Abstract)
27. Burroughs LM, Maris MB, Sandmaier BM, Leisenring W, Jain Stuart M, Niederwieser D, McSweeney PA, Chauncey T, Maziarz R, Agura E, **Little M-T**, Blume KG, Storb R, Maloney DG. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). *Biol Blood Marrow Transplant* 10 (Suppl. 1): 73-74, #197, 2004.(Abstract)
28. Sorrow ML, Maris MB, Sandmaier BM, Jain-Stuart M, Storer B, Hegenbart U, McSweeney P, Chauncey T, Bruno B, Wade J, Agura E, Pulsipher M, Leis J, **Little M-T**, Niederwieser D, Blume K, Storb R, Maloney DG. Treatment of patients (PTS) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD). *Biol Blood Marrow Transplant* 10 (Suppl. 1): 26-27, 2004.(Abstract)
29. Baron F, Maris M, Storer B, Sandmaier B, Panse J, Chauncey T, Sorrow M, **Little M-T**, Maloney D, Storb R, Heimfeld S. Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation. *Blood* 104:2753, 2004. (Abstract)
30. Diaconescu R, Leisenring W, Kahl C, Sorrow M, Zellmer E, Maris M, **Little MT**, Storb R Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism. *Blood* 104:1202, 2004 (Abstract)

## CURRICULUM VITAE

Marie-Térèse, E., Little, BSc., MSc., PhD

---

### INVITED LECTURES

- 04/02 "Hematopoietic stem cell transplantation in Duchenne muscular dystrophy- Preliminary Findings". European DMD Collaborators Conference. Nijmegen, The Netherlands
- 07/02 "Haematopoietic Cell Transplantation in Dogs with DMD", Seattle Muscular Dystrophy Conference, Seattle, WA, USA
- 06/03 "Haematopoietic Cell Transplantation in Dogs with DMD", MDA -Emerging Therapies Meeting, Tucson, Arizona,
- 06/04 Muscular Dystrophy Association Conference, University of Washington, Seattle, WA, USA
- 07/04 "Allogeneic Haematopoietic Stem Cell Transplantation for Canine X-linked Muscular Dystrophy", PPMD Annual Conference, Pittsburgh, PA, USA
- 09/04 "Model for Gene Therapy-Allogeneic Haematopoietic Stem Cell Transplantation for Canine X-linked Muscular Dystrophy", Seattle Muscular Dystrophy Conference, Seattle, WA
- 02/06 "Nonmyeloablative Conditioning and Haematopoietic Cell Transplantation- Preclinical to Clinical", Invited Guest Speaker, Grand Rounds, BC Cancer Agency, Victoria, BC, Canada
- 04/18 "Reviewing Clinical Trials-New Proposal and New Protocol Review- A Lay Representative Perspective", CCTG Annual Spring Meeting, Toronto, Ontario, Canada